sciencenewsnet.in

How the Covid-19 Pandemic Has Changed Clinical Trials

Dr. Reynold Panettieri vice chancellor for Translational Medicine and Science and director of Rutgers Institute for Translational Medicine and Science, which is part of a Rutgers-led team that recently received a $29-million grant from the National Institutes of Health to translate clinical research into patient care and treatment more quickly stands in front of the Child health Institute of New Jersey

Reynold Panettieri, vice chancellor for Translational Medicine and Science at Rutgers University, is available to discuss how the Covid-19 pandemic has changed how clinical trials are administered.

“A crisis, such as the pandemic, requires a nimble approach and streamlining operations. Clinical research has historically been a bricks-and-mortar operation that required people to come to a building and relied on paper consents and reports. Now, all forms and reports are electronic and visits are done by telemedicine,” he says. “Procedures have been streamlined as researchers have to move fast. Contracting, budgeting and institutional review board approvals that could take up to nine months now can be done in less than a week.”